Cybin Inc.
NEO: CYBNÂ NYSE American: CYBN
Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin’s mission is to revolutionize mental healthcare.
In December 2020, Cybin acquired Adelia Therapeutics, growing their patent filings to over half a dozen applications.
[mstock id="3405"]
[mstock id="3391"]
The potential of psychedelic therapies to treat mental illness and addiction disorders has never been more significant. With this [$45m] investment, we will continue to advance our robust pipeline of psychedelic-based products through clinical development.
